Tamoxifen Resistance: Emerging Molecular Targets

Area of Science:

• Oncology
• Endocrinology
• Molecular Biology

Background:

• 17β-Estradiol (E2) is crucial in estrogen receptor (ER) positive breast cancer development.
• Tamoxifen (TAM) and aromatase inhibitors are key therapies blocking E2 signaling.
• TAM resistance, occurring de novo or acquired, hinders effective endocrine therapy.

Purpose of the Study:

• To review the implications of TAM in breast cancer.
• To explore molecular mechanisms underlying TAM resistance.
• To identify novel therapeutic targets and prognostic indicators.

Main Methods:

• Literature review focusing on TAM's biological activity and resistance mechanisms.
• Analysis of emerging receptors and signaling pathways involved in estrogenic signaling.
• Examination of studies investigating G protein-coupled estrogen receptor, Androgen Receptor, and Hedgehog pathways.

Main Results:

• TAM resistance is multifactorial and not fully understood.
• G protein-coupled estrogen receptor, Androgen Receptor, and Hedgehog pathways are implicated in TAM resistance.
• These pathways mediate estrogenic signaling in both ERα-positive and ERα-negative breast cancer.

Conclusions:

• Understanding TAM's molecular effects is crucial for overcoming resistance.
• Novel targets like GPCR, AR, and Hedgehog pathways offer potential for improved breast cancer treatment.
• These targets may serve as prognostic indicators for patient outcomes.